Health Catalyst (HCAT) EBIAT (2018 - 2025)
Health Catalyst (HCAT) has disclosed EBIAT for 8 consecutive years, with -$22.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 50.95% year-over-year to -$22.2 million, compared with a TTM value of -$107.6 million through Sep 2025, down 35.99%, and an annual FY2024 reading of -$69.5 million, up 41.17% over the prior year.
- EBIAT was -$22.2 million for Q3 2025 at Health Catalyst, up from -$41.0 million in the prior quarter.
- Across five years, EBIAT topped out at -$13.5 million in Q2 2024 and bottomed at -$49.0 million in Q4 2021.
- Average EBIAT over 5 years is -$29.7 million, with a median of -$30.3 million recorded in 2023.
- The sharpest move saw EBIAT surged 58.56% in 2024, then crashed 203.18% in 2025.
- Year by year, EBIAT stood at -$49.0 million in 2021, then increased by 26.96% to -$35.8 million in 2022, then grew by 15.29% to -$30.3 million in 2023, then soared by 31.8% to -$20.7 million in 2024, then dropped by 7.53% to -$22.2 million in 2025.
- Business Quant data shows EBIAT for HCAT at -$22.2 million in Q3 2025, -$41.0 million in Q2 2025, and -$23.7 million in Q1 2025.